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ad, UK.Summary Background: Chronic obstructive pulmonary disease (COPD) is char-
acterised by airway inflammation, poor health status and recurrent infective
exacerbations. Macrolide antibiotics have been shown to improve symptoms and
exacerbation rate in chronic lung disease, particularly cystic fibrosis (CF) and diffuse
pan-bronchiolitis. The effect of long-term oral clarithromycin on health status,
sputum bacterial numbers and exacerbation rate in subjects with clinically stable
COPD is undetermined.
Methods: Subjects with moderate-to-severe COPD were recruited into a
prospective, double-blind, randomised-controlled trial of 3-months oral clarithro-
mycin (Klaricid XL) or placebo once-daily. The effect of clarithromycin on health
status (St. George respiratory and Short Form-36 questionnaires), sputum quanti-
tative bacterial numbers and exacerbation rate were investigated.
Results: Sixty-seven subjects (46 males) were recruited; 31 and 36 subjects
received clarithromycin and placebo, respectively. There were 7(10%) withdrawals.
Compared to placebo, clarithromycin did not significantly improve health status,
sputum bacterial numbers, or exacerbation rate.
Conclusions: Three months of oral clarithromycin given to subjects with stable
COPD does not improve health status, sputum bacterial numbers or exacerbation
rate. Treatment of COPD with clarithromycin during the clinical stable state yields
no clinical advantages and therefore cannot be recommended as means of
eliminating sputum bacteria or preventing infective exacerbations.
r 2004 Elsevier Ltd. All rights reserved.4 Elsevier Ltd. All rights reserv
1-424-2000; fax: +44-121-
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rch grant from Abbott UKIntroduction
Chronic obstructive pulmonary disease (COPD) is a
chronic, slowly progressive disorder characteriseded.
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markedly over several months and is a major cause
for morbidity and mortality.1 COPD is characterised
by airway inflammation, impaired health status,
exercise limitation, and recurrent infective exacer-
bations. Macrolide antibiotics have been shown to
exhibit both anti-inflammatory and anti-bacterial
properties.2 Macrolides, such as clarithromycin,
have been commonly used in the treatment of
acute infective exacerbations of COPD, showing
adequate clinical symptom and bacteriological
improvement.3–5 Macrolides have also an important
clinical role in the treatment of diffuse pan-
bronchiolitis with recognised improvements in
mortality,6 symptoms7 and spirometry;8 and cystic
fibrosis (CF) with evidence for improved health
status, spirometry and exacerbation rates.9,10 More
recently, there have been data suggesting that oral
azithromycin may improve spirometry in lung
transplant recipients suffering from bronchiolitis
obliterans syndrome.11
The use of prophylactic antibiotics to eliminate
bacteria from the bronchial airways and prevent
infective exacerbations of COPD whilst in the
clinical stable state remains controversial. Routine
therapy at present is not recommended,12 but this
statement is based on trials conducted over 30
years ago where antibiotic sensitivity and the range
of antibiotics available may have been different.
The prescribing of antibiotics, continuously or
intermittently, in such subjects, however, remains
commonplace. As yet, there have been no pub-
lished randomised, placebo-controlled trials look-
ing at the effect of macrolide antibiotics on health
status, quantitative sputum bacterial loads, and
infective exacerbation rates in subjects with COPD
during the stable clinical state. The aim of the
study was to determine whether 3 months oral
clarithromycin (Klaricid XL 500mg once daily)
improves health status, diminish sputum bacterial
numbers and reduce exacerbation rates in such
subjects compared to placebo.Methods
Patients
Subjects were recruited from the City Hospital,
Birmingham and Birmingham Heartlands Hospital
clinics and lung function units. All subjects entering
the trial gave written informed consent and had the
diagnosis of moderate-to-severe COPD according to
the British Thoracic Society (BTS) guidelines.1 Thus,
all subjects had a history of chronic progressivesymptoms (cough and/or wheeze and/or breath-
lessness) and post-bronchodilator objective evi-
dence of airways obstruction by spirometric
testing. All subjects had a FEV1=VC ratio of less
than 70%, FEV1% predicted of less than 60% (i.e.
moderate-to-severe) and a less than 200ml or 15%
(of baseline) increase in FEV1 to a beta-agonist
bronchodilator. Current smokers were regarded as
those individuals who had smoked regularly over at
least 6 months before the recruitment date.
Subjects with any previous documented allergies
to macrolide antibiotics, a recent infective exacer-
bation within the last 6 weeks or a clinical history
of asthma, bronchiectasis, lung cancer and uncon-
trolled ischaemic heart disease or diabetes mellitus
were excluded. Based on observations that many
moderate-to-severe patients in clinical practice are
on inhaled corticosteroids and that there is growing
evidence that withdrawal of these may have a
detrimental effect on clinical state,13,14 it was
decided that only those subjects taking inhaled
corticosteroids would be recruited.Study design
The subjects underwent a run-in period of 2 weeks
to ensure stability of disease. Subjects were then
block randomised into a prospective, double-blind
controlled study of oral clarithromycin (Klaricid XL)
500mg once daily (Abbott UK Ltd., Maidenhead, UK)
or placebo once daily for 3 months. Patients were
randomised by the Birmingham Heartlands Hospital
pharmacy department, independent of trial staff.
The trial was approved by the City Hospital,
Birmingham and Birmingham Heartlands Hospital
ethics committees. Subjects continued to take their
baseline medications as prescribed by their primary
care physician. All subjects were regularly in
contact to encourage full compliance, with tablet
counts and documentation of adverse events.
Subjects were asked to report changes in symptoms
suggestive of an infective exacerbation.15 The
primary endpoint was health status and secondary
endpoints included sputum bacterial quantitative
load, infective exacerbation rate, shuttle walk test
and serum C-reactive protein levels (CRP). These
were assessed initially after 2 weeks of the run-in
i.e. day 1 and then 3 months later during the last
week of treatment. Analyses of parameters were
conducted on an intention to treat basis.Assessments
Spirometry (FEV1, FVC and FEV1=FVC) was mea-
sured using a MIR Spirobank electronic device
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FEV1 was assessed by repeating spirometric tests
20 min after inhalation of salbutamol ð400mgÞ given
through a volume spacer by a trained member of
the lung function department. Static lung volumes
were measured at the City Hospital, Birmingham
lung function unit by body box and gas transfer
using single breath carbon monoxide method
(V6200 Autobox, Sensormedics, USA). Health status
was measured using the St. George respiratory
questionnaire (SGRQ ) as a disease-specific assess-
ment of symptoms, activity and impact. The Short-
Form 36-item questionnaire (SF-36) was also used
as a general health measure covering eight health
concepts; physical functioning, social functioning,
physical role limitation, emotional role limitation,
mental health, pain index, vitality and general
health perception. The shuttle walk test was used
to assess functional capacity as previously de-
scribed and validated.16 Hypertonic (3%) saline
induction using a De Vilbiss ultrasonic nebuliser
(output 2:2ml=min) via a mouth piece was under-
taken to obtain sputum samples for quantitative
bacterial assays. The nebulisation procedure was
stopped if the patient wished to do so or if the FEV1
fell by more than 20% compared to baseline after
the first nebulisation period with the judgement
(made by the operator) that it would be unsafe to
continue.
Quantitative bacterial culture measurements
on the sputum were carried out as previously
described by Pye et al..17 The sputum sample
was homogenised using an equal volume of Spu-
tasol (Oxoid Ltd., Basingstoke, UK; containing
100mg=ml dithiothreitol), diluted in sterile saline
(0.9% NaCl) and inoculated onto chocolate, blood,
and MacConkey agar plates. All plates were
incubated at 36 1C in an atmosphere of 5% CO2 in
air and examined for bacterial growth after 24
and 48 h. Colonies on the plates were counted and
the viable bacterial numbers present were ex-
pressed as colony-forming units (cfu)/ml of the
original sputum. Sputasol has been shown not to
affect bacterial viability.17 Bacterial patho-
gens recovered were regarded as potential patho-
genic microorganisms (PPMs) or non-potential
pathogenic microorganisms (non-PPMs). In the
current study, PPMs included the respiratory bac-
terial pathogens e.g. Haemophilus influenzae,
Streptococcus pneumoniae, Mycobacterium catar-
rhalis, Haemophilus parainfluenzae, Staphylococ-
cus aureus, Pseudomonas aeruginosa, Klebsiella
pneumoniae and the following were regarded as
non-PPMs: S.viridans, Neisseria spp, Corynebacter-
ium spp, Candida spp, Enterococcus spp, and
coagulase-negative staphylococcus. These studieswere carried out by the appropriate technical
support.
Statistical analysis
Statistical analyses were performed using a SPSS
version 10.0 (Chicago, USA) package. To determine
whether the distributions of all continuous data
were normal, a Kolmogorov–Smirnov test was
performed. Where such an assumption could not
be met, the data were summarised in terms of
medians and interquartile ranges (IQR) rather than
means and standard errors (SE). In order to compare
data of a parameter before and after an interven-
tion, the mean change in the parameter in the
active group was compared to the mean change in
the parameter in the placebo group using para-
metric (non-paired two-independent group t-test)
or non-parametric (Mann–Whitney U-test) testing
where appropriate. Analysing the change in the
parameter value eliminated any pre-treatment
discrepancies between the placebo and clarithro-
mycin groups. Bacterial numbers i.e. cfu were log
transformed in order to normalise the data. Two-
tailed tests were used and the level of significance
was taken as Po0:05. Any statistical significant
findings or findings of relevance are presented as a
size of effect i.e. mean difference with 95%
confidence intervals (95% CI). A sample size of 50
(25 in each group) was required to detect a
difference of 0.8SD (standardised difference) in
the mean change of health status score in the
clarithromycin group compared to the placebo
group. With an allowance for a 25% patient drop
out/exclusion rate or missing data, 66 subjects
were necessary assuming these exclusions. These
calculations were based on an a ¼ 0:05; b ¼ 20%
hence a power of 80%.Results
Patients
Sixty-seven subjects (46 males) screened for the
trial were entered and randomised to receive
clarithromycin ðn ¼ 31Þ and placebo ðn ¼ 36Þ. Both
groups were similar for age, body mass index (BMI),
smoking history and lung function. Table 1 shows
the baselines values for lung function, shuttle walk
distance, health status scores and CRP levels for
both groups. SGRQ total, impact, symptom, SF-36
physical functioning, bodily pain and physical role
limitation scores were significantly different be-
tween the two groups at the outset. All subjects
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Table 1 Baseline demographic, lung function, shuttle walk distance, health status scores and CRP for the
clarithromycin and placebo groups.
Parameter Clarithromycin ðn ¼ 31Þ Placebo ðn ¼ 36Þ P value
Age (years) 65:1 ð1:4Þ 68:1 ð1:2Þ NS
BMI ðkg=m2Þ 24:7 ð0:9Þ 24:3 ð1:0Þ NS
Current smoker 45% 64% NS
Cigarette pack-years 58 ð5:6Þ 59 ð3:8Þ NS
FEV1 observed (l) 1:12 ð0:07Þ 1:13 ð0:07Þ NS
FEV1 % predicted 42:5 ð2:0Þ 43:9 ð2:0Þ NS
FVC observed (l) 2:57 ð0:15Þ 2:53 ð0:14Þ NS
FVC % predicted 78:4 ð2:9Þ 76:8 ð2:8Þ NS
FEV1=FVC observed 43:8 ð1:6Þ 45:5 ð2:1Þ NS
TLC % predicted 112 ð2:4Þ 119 ð2:2Þ NS
RV % predicted 177 ð10:5Þ 162 ð5:7Þ NS
RV/TLC % predicted 154 ð5:7Þ 144 ð3:7Þ NS
DLCO % predicted 52 ð3:2Þ 50 ð2:5Þ NS
KCO % predicted 70 ð3:2Þ 67 ð3:0Þ NS
Shuttle walk distance (m) 179 ð24:4Þ 223 ð21:7Þ NS
Total SGRQ 57 ð3:9Þ 47 ð2:5Þ 0.03
SGRQ impact 45 ð3:2Þ 34 ð2:7Þ 0.01
SGRQ symptom 69 ð3:2Þ 60 ð3:3Þ 0.04
SGRQ activity 73 ð2:1Þ 65 ð3:3Þ NS
SF-36 general health perception 31 ð2:5Þ 41 ð3:5Þ NS
SF-36 physical functioning 31 ð2:5Þ 47 ð3:8Þ 0.01
SF-36 bodily pain 52 ð3:3Þ 69 ð4:0Þ 0.01
SF-36 vitality 34 ð2:4Þ 42 ð3:8Þ NS
SF-36 physical role limitation* 0 (0–12) 12 (0–81) 0.03
SF-36 emotional role limitation* 100 (33–100) 100 (33–100) NS
SF-36 social functioning* 75 (25–100) 100 (46–100) NS
SF-36 mental health* 68 (48–82) 78 (56–88) NS
CRP (mg/dl) 8:7 ð1:7Þ 9:6 ð1:4Þ NS
BMI ¼ body mass index, FEV1 ¼ forced expiratory volume in 1 s, FVC ¼ forced vital capacity, TLC ¼ total lung capacity,
RV ¼ residual volume, DLCO ¼ gas transfer, KCO ¼ corrected gas transfer, SGRQ ¼ St: George respiratory questionnaire,
SF-36 ¼ short form-36. CRP ¼ C reactive protein, NS ¼ not significant.
*Denotes non-parametric data and are presented as median (IQR), parametric data are presented as mean (SE).
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no abandonments from this procedure.
All subjects recruited were taking an inhaled
corticosteroid, 12 (18%) were taking long-acting
beta-2 agonists and 42 (63%) were taking inhaled
anticholinergics. There were equal proportions of
those taking long-acting beta-2 agonists and antic-
holinergics in both groups. Seven subjects (10%)
were lost to follow-up without completing the
course and hence were regarded as missing data
(five from the clarithromycin group and two from
the placebo group). One patient from the clari-
thromycin group had a gastrointestinal upset and
did not wish to complete the course. Four subjects
(three from the clarithromycin group and one from
the placebo group) were unable to attend follow-up
due to continued poor health following an infective
exacerbation and two (one from each group)admitted poor compliance and both withdrew
voluntarily. In total, 26 subjects receiving clari-
thromycin and 34 receiving placebo completed the
course and intention to treat analyses were there-
fore performed on a total of 60 patients.Health status, shuttle walk distance,
spirometry, and CRP
In general, clarithromycin did not show any
advantageous trends in health status scores when
compared to placebo. There was a significant
improvement in the SGRQ symptom score (mean
difference (95%CI)=10.2 (1.6–18.7) units, P ¼ 0:04).
Improvement was not seen in any other SGRQ
domains. There was no overall significant improve-
ment in the SF-36 health status scores except for
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Figure 1 The effect of clarithromycin and placebo on
sputum cfu numbers/bacterial (PPM) isolate. Cfu num-
bers are logged. Weighted bars indicate the mean for the
whole group. There was no statistically significant
difference between pre- and post- cfu numbers for both
clarithromycin and placebo groups. NS indicates not
significant.
D. Banerjee et al.212SF-36 physical functioning score (mean difference
(95%CI)=12.9 (3.1–22.6) units, P ¼ 0:01). Compared
to placebo, 3 months of clarithromycin did not
significantly improve shuttle walk distance, spiro-
metry or CRP levels.
Exacerbations and sputum quantitative
bacterial assessment
In total, there were five infective exacerbations in
the clarithromycin group and two in the placebo
group during 3 months of treatment. This differ-
ence was not significantly different ðP ¼ 0:24Þ.
H.influenzae (12 isolates), S.pneumoniae (nine
isolates) and M.catarrhalis (seven isolates) species
accounted for 90% of the total number of bacterial
isolates at the outset. S.aureus, K.pneumoniae,
P.aeruginosa, Coliform spp. and Acinetobacter spp.
accounted for the other 10%. Some subjects had
more than one PPM in their sputum. After 3 months
of clarithromycin, the number of subjects with
sputum PPMs increased from 12 to 15 and the
number of bacterial isolates16 did not change. In
the placebo group, the number of subjects with
sputum PPMs increased from 10 to 16 and the
number of bacterial isolates increased from 15 to
25. Clarithromycin, when compared to placebo, did
not significantly reduced the mean number of
H.influenzae, S.pneumoniae, or M.catarrhalis cfu
(log)/bacterial isolate (Table 2). No multi-resistant
gram-negative organisms emerged in the clarithro-
mycin group. When all the PPM isolates were taken
together as a group, clarithromycin did not
significantly change the mean cfu (log) number
per bacterial isolate compared to placebo. TheseTable 2 The effect of clarithromycin and placebo on th
(log)/bacterial isolate.
Clarithrom
Mean (log)
H.influenzae Pre- 8:06 ð0:52Þ
Post- 8:46 ð0:54Þ
P value NS
S.pneumoniae Pre- 8:61 ð0:40Þ
Post- 7:88 ð0:44Þ
P value NS
M.catarrhalis Pre- 8:13 ð0:46Þ
Post- 9:59 n ¼ 1
P value NS
All PPMs Pre- 8:28 ð0:29Þ
Post- 8:38 ð0:35Þ
P value NS
Cfu numbers were logged to normalise the data. NS indicates nofindings are shown by means of a scatter plot
(Fig. 1).Discussion
This randomised-controlled trial in stable subjects
with moderate-to-severe COPD found that 3 monthse sputum mean (SE) colony forming unit (cfu) numbers
ycin Placebo
cfu (SE)/isolate Mean (log) cfu (SE)/isolate
n ¼ 7 8:96 ð0:58Þ n ¼ 5
n ¼ 9 7:46 ð0:62Þ n ¼ 8
NS
n ¼ 6 8:33 ð0:09Þ n ¼ 3
n ¼ 5 7:71 ð0:47Þ n ¼ 9
NS
n ¼ 3 7:82 ð0:76Þ n ¼ 4
7:16 ð0:54Þ n ¼ 5
NS
n ¼ 16 8:50 ð0:30Þ n ¼ 15
n ¼ 16 7:69 ð0:29Þ n ¼ 25
NS
t significant.
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nificantly change health status, sputum bacteriol-
ogy or exacerbation rate. There were no changes in
spirometry, shuttle walk test or CRP levels as well.
To our knowledge from the available literature, this
is the first study investigating the effect low dose 3-
months oral clarithromycin on health status,
bacteriology and exacerbation rate in patients with
COPD during the clinical stable state.
Although, two health status domains in this
current study were significantly improved in clar-
ithromycin group, their clinical significance is
unclear in the absence of any other positive
changes. The clinical role of macrolides in other
chronic lung diseases has been investigated else-
where. Long-term low-dose erythromycin in pan-
bronchiolitis has been shown by Nagai et al. to
demonstrate a significant reduction in dyspnoea
and cough7 and by Kudoh et al. to show an
improved survival.18 The mechanism is thought to
be anti-inflammatory rather than antibacterial.19 In
subjects with CF, 3 months of oral azithromycin
detected improvements in dyspnoea, fatigue, and
total health status scores using the Chronic
Respiratory Disease Questionnaire.10 This latter
study also showed a small improvement in spiro-
metry and a reduction in the exacerbation rate
when compared to placebo. The improvement in
symptoms may be due to an improvement in
spirometry and exacerbation rate. However, other
trials in CF have not shown similar improvements in
spirometry or bacteriology,20,21 although one of
these trials implied a reduced need for multiple
antibiotic courses.20 A recent Cochrane review on
the role of macrolides in stable CF concluded that
the exact role of these antibiotics in this condition
remains unclear and that more clinical trials are
needed before widespread usage is recom-
mended.22 There has been no similar review of
the use of macrolides in COPD.
The choice of clarithromycin was made on the
basis of its better side-effect profile compared to
other macrolides, especially erythromycin. Clari-
thromycin also comes as an extended release form
(Klaricid XL 500mg) which allows once daily dosing.
Once daily dosing of clarithromycin has been shown
to result in adequate drug levels in the plasma and
bronchial epithelial lining fluid.23 It was believed
that these factors would encourage good compli-
ance. In general, clarithromycin was well tolerated
with very few side effects and only one withdrawal
(gastrointestinal upset) directly related to this
drug. Subjects enrolled into this study typified the
heterogeneous nature of COPD, i.e. differing
smoking histories and therapeutic regimens.
Although, all subjects in this trial with moderate-to-severe COPD were taking inhaled corticoster-
oids, inhaled corticosteroids are not currently
regarded as mandatory treatment for those with
moderate COPD only. How differing smoking his-
tories and inhaler usage may have influenced the
endpoint results are unknown. However, it was felt
that the 67 subjects enrolled would typically
reflect the type of subject with COPD that primary
and secondary care physicians would commonly
encounter in their practice. In this present study,
however, the results for 60 subjects were available
for full analysis and a larger study may give more
meaningful outcomes.
The length of treatment in this study was 3
months. Although the trial resulted in no positive
outcomes, the effect of long-term i.e. more than 3
months, clarithromycin on parameters such as
health status, bacteriology, exacerbation rates
and spirometry is unclear and hence further longer
studies may be necessary to determine this. Any
clinically meaningful improvements in spirometry
and exacerbation rate may only be seen after long-
term therapy, although it is doubtful that long-term
therapy would lead to significant sputum bacter-
iological clearance that was not achieved in the
present study after 3 months. A further long-term
follow-up in this trial, however, may have detected
a beneficial effect.
The lack of effect of clarithromycin on bacterial
colony numbers in sputum in subjects with stable
COPD is interesting, as this would contradict
previous studies of clarithromycin in subjects with
acute exacerbations of chronic bronchitis or COPD.
These trials have shown adequate bacterial eradi-
cation in between 70% and 95% of patients.3,4
H.influenzae, S.pneumoniae and M.catarrhalis con-
tribute to the majority of bacterial exacerbations,
but in this current work clarithromycin did not
affect the number of these bacterial isolates nor
the mean cfu number per isolate whilst in the
clinical stable state. It may be possible that an
absence of effect of antibiotic on bacterial num-
bers may be a result of a lack of compliance in this
trial. However, regular checks of compliance were
carried out by the trial team, and only two subjects
were deemed as insufficient compilers. It has been
suggested that in vitro tests underestimate the
clinical utility of this drug because of the added
antibacterial effects of clarithromycin and its 14-
hydroxy metabolite.24 The minimum inhibitory
concentration-90 ðMIC90Þ of clarithromycin for
H.influenzae is higher than other bacterial species,
e.g. M.catarrhalis, suggesting reduced susceptibil-
ity.25 This current study did not measure MIC90
which may be useful in any further similar
antibiotic trials to detect changes in antibiotic
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particularly important if oral antibiotics are con-
sidered as prophylactic measures long term. There
was no emergence of multi-drug-resistant gram-
negative bacterial species in those subjects taking
clarithromycin. Other trials assessing the effect of
other antibiotics, such as penicillins or cephalos-
porins, given continuously during the stable state
using a similar design to the current study may be
worthwhile as it is possible that any positive effect
on health status, bacteriology and exacerbation
rate may be found in other antibiotic groups and
not clarithromycin.
In conclusion, this randomised-controlled trial
has shown that oral clarithromycin given for 3-
months in subjects with moderate-to-severe stable
COPD, had no advantageous effect on health
status, sputum bacteriology or exacerbation rate.
Therefore, the treatment of subjects with stable
COPD with clarithromycin to obtain an improve-
ment in health status, achieve sputum bacterial
clearance, and reduce the number of infective
exacerbations may need further larger long-term
studies.Acknowledgements
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